A Safety, Tolerability, Pharmacokinetics and Immunogenicity Trial of Co-administered MERS-CoV Antibodies REGN3048 and REGN3051

• ClinicalTrials.gov Identifier: NCT03301090
• Recruitment Status: Completed
• First Posted: October 4, 2017
• Last Update Posted: February 1, 2019
• Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
• Information provided by (Responsible Party): National Institute of Allergy and Infectious Diseases (NIAID)

Study Description

Brief Summary:

This is a Phase 1, first-in-human (FIH), single site, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of single ascending doses of a co-administered (1:1, w/w) combination of REGN3048 and REGN3051 mAb's, administered IV in healthy adult volunteers. Study duration of approximately 16 months. Approximately 48 evaluable subjects will be enrolled in the study, eight (8) subjects in each one of 6 sequential ascending IV dose cohorts. In each cohort, subjects will be randomized to receive mAb's REGN3048 and REGN3051 (6 subjects) or placebo (2 subjects). Primary Objective: To assess the safety and tolerability of REGN3048 and REGN3051 following co-administration of single, ascending IV doses of 1.5, 5, 15, 25, 50, and 75 mg/kg of each of the two mAb's.

Condition or disease	Intervention/treatment	Phase
Corona Virus Infection	Other: Placebo; Biological: REGN3048; Biological: REGN3051	Phase 1

Detailed Description:

This is a Phase 1, first-in-human (FIH), single site, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of single ascending doses of a co-administered (1:1, w/w) combination of REGN3048 and REGN3051 mAb's, administered IV in healthy adult volunteers. Study duration of approximately 16 months. Approximately 48 evaluable subjects will be enrolled in the study, eight (8) subjects in each one of 6 sequential ascending IV dose cohorts. In each cohort, subjects will be randomized to receive mAb's REGN3048 and REGN3051 (6 subjects) or placebo (2 subjects). Primary Objective: To assess the safety and tolerability of REGN3048 and REGN3051 following co-administration of single, ascending IV doses of 1.5, 5, 15, 25, 50, and 75 mg/kg of each of the two mAb's. Secondary Objectives: 1) To assess the pharmacokinetic (PK) profiles of REGN3048 and REGN3051 following co-administration of single IV doses (1.5, 5, 15, 25, 50, and 75 mg/kg of each of the two mAb's); 2) To assess the immunogenicity of REGN3048 and REGN3051 following co-administration of single IV doses (1.5, 5, 15, 25, 50, and 75 mg/kg of each of the two mAb's)

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 48 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Double (Participant, Investigator)
• Primary Purpose: Treatment
• Official Title: A Phase I Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Co-administered MERS-CoV Antibodies REGN3048 and REGN3051 vs. Placebo in Healthy Adults
• Actual Study Start Date: February 12, 2018
• Actual Primary Completion Date: January 19, 2019
• Actual Study Completion Date: January 19, 2019

Arms and Interventions

Arm	Intervention/treatment
Experimental: Cohort A; REGN3048+REGN3051 3 mg/kg (1.5 mg/kg of each mAb) single infusion IV, n=6; placebo IV, n=2	Other: Placebo; Placebo; Biological: REGN3048; REGN3048 is a fully monoclonal antibody (mAbs) which binds to the S protein of MERS-CoV.; Biological: REGN3051; REGN3051 is a fully human monoclonal antibody (mAb) which binds to the S protein of MERS-CoV. It can reduce virus titers and ameliorate MERS-CoV-induced lung pathology when given post infection.
Experimental: Cohort B; REGN3048+REGN3051 10 mg/kg (5 mg/kg of each mAb) single infusion IV, n=6; placebo IV, n=2	Other: Placebo; Placebo; Biological: REGN3048; REGN3048 is a fully monoclonal antibody (mAbs) which binds to the S protein of MERS-CoV.; Biological: REGN3051; REGN3051 is a fully human monoclonal antibody (mAb) which binds to the S protein of MERS-CoV. It can reduce virus titers and ameliorate MERS-CoV-induced lung pathology when given post infection.
Experimental: Cohort C; REGN3048+REGN3051 30 mg/kg (15 mg/kg of each mAb) single infusion IV, n=6; placebo IV, n=2	Other: Placebo; Placebo; Biological: REGN3048; REGN3048 is a fully monoclonal antibody (mAbs) which binds to the S protein of MERS-CoV.; Biological: REGN3051; REGN3051 is a fully human monoclonal antibody (mAb) which binds to the S protein of MERS-CoV. It can reduce virus titers and ameliorate MERS-CoV-induced lung pathology when given post infection.
Experimental: Cohort D; REGN3048+REGN3051 50 mg/kg (25 mg/kg of each mAb) single infusion IV, n=6; placebo IV, n=2	Other: Placebo; Placebo; Biological: REGN3048; REGN3048 is a fully monoclonal antibody (mAbs) which binds to the S protein of MERS-CoV.; Biological: REGN3051; REGN3051 is a fully human monoclonal antibody (mAb) which binds to the S protein of MERS-CoV. It can reduce virus titers and ameliorate MERS-CoV-induced lung pathology when given post infection.
Experimental: Cohort E; REGN3048+REGN3051 100 mg/kg (50 mg/kg of each mAb) single infusion IV, n=6; placebo IV, n=2	Other: Placebo; Placebo; Biological: REGN3048; REGN3048 is a fully monoclonal antibody (mAbs) which binds to the S protein of MERS-CoV.; Biological: REGN3051; REGN3051 is a fully human monoclonal antibody (mAb) which binds to the S protein of MERS-CoV. It can reduce virus titers and ameliorate MERS-CoV-induced lung pathology when given post infection.
Experimental: Cohort F; REGN3048+REGN3051 150 mg/kg (75 mg/kg of each mAb) single infusion IV, n=6; placebo IV, n=2	Other: Placebo; Placebo; Biological: REGN3048; REGN3048 is a fully monoclonal antibody (mAbs) which binds to the S protein of MERS-CoV.; Biological: REGN3051; REGN3051 is a fully human monoclonal antibody (mAb) which binds to the S protein of MERS-CoV. It can reduce virus titers and ameliorate MERS-CoV-induced lung pathology when given post infection.

Outcome Measures

Primary Outcome Measures :

1. Changes from baseline in abbreviated physical examination [ Time Frame: Days 1-2 ]
2. Changes from baseline in clinical safety laboratory values [ Time Frame: From Day 2 up to Day 121 ]
3. Changes from baseline in Electrocardiogram (ECG) parameters [ Time Frame: 15 mins after infusion ]
4. Changes from baseline in Electrocardiogram (ECG) parameters [ Time Frame: 24 hrs after infusion ]
5. Changes from baseline in symptom-directed physical examination [ Time Frame: From Day 1 up to Day 121 ]
6. Changes from baseline in vital signs [ Time Frame: From Day 1 up to Day 121 ]
7. The incidence of Adverse Events [ Time Frame: From Day 1 up to Day 121 ]
8. The incidence of treatment-emergent Serious Adverse Events [ Time Frame: From Day 1 up to Day 121 ]
9. The severity of Adverse Events assessed by toxicity grading criteria [ Time Frame: From Day 1 up to Day 121 ]
10. The severity of treatment-emergent Serious Adverse Events assessed by toxicity grading criteria [ Time Frame: From Day 1 up to Day 121 ]
11. The type of treatment-emergent Serious Adverse Events [ Time Frame: From Day 1 up to Day 121 ]

Secondary Outcome Measures :

1. AUC for each dose of REGN3048 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs) [ Time Frame: From Day 1 up to Day 121 ]
2. AUC for each dose of REGN3051 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs) [ Time Frame: From Day 1 up to Day 121 ]
3. AUC(0-infinity) for each dose of REGN3048 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs) [ Time Frame: From Day 1 up to Day 121 ]
4. AUC(0-infinity) for each dose of REGN3051 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs) [ Time Frame: From Day 1 up to Day 121 ]
5. CL for each dose of REGN3048 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs) [ Time Frame: From Day 1 up to Day 121 ]
6. CL for each dose of REGN3051 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs) [ Time Frame: From Day 1 up to Day 121 ]
7. CMAX for each dose of REGN3048 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs) [ Time Frame: From Day 1 up to Day 121 ]
8. CMAX for each dose of REGN3051 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs) [ Time Frame: From Day 1 up to Day 121 ]
9. K(e) for each dose of REGN3048 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs) [ Time Frame: From Day 1 up to Day 121 ]
10. K(e) for each dose of REGN3051 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs) [ Time Frame: From Day 1 up to Day 121 ]
11. t(1/2) for each dose of REGN3048 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs) [ Time Frame: From Day 1 up to Day 121 ]
12. t(1/2) for each dose of REGN3051 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs) [ Time Frame: From Day 1 up to Day 121 ]
13. The change from baseline of antibodies against REGN3048 and REGN3051 (anti-drug antibodies, ADA), as measured in serum using validated bridging assays [ Time Frame: Day 121 ]
14. The change from baseline of antibodies against REGN3048 and REGN3051 (anti-drug antibodies, ADA), as measured in serum using validated bridging assays [ Time Frame: Day 57 ]
15. TMAX for each dose of REGN3048 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs) [ Time Frame: From Day 1 up to Day 121 ]
16. TMAX for each dose of REGN3051 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs) [ Time Frame: From Day 1 up to Day 121 ]
17. V(ss) for each dose of REGN3048 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs) [ Time Frame: From Day 1 up to Day 121 ]
18. V(ss) for each dose of REGN3051 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs) [ Time Frame: From Day 1 up to Day 121 ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 45 Years (Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

All must be answered yes for the subject to be eligible for study participation

1. Informed consent understood and signed prior to initiation of any study procedures
2. Healthy male or healthy, non-pregnant, non-lactating female, meeting eligibility criteria as assessed by the clinicians listed on the FDA Form 1572
3. Willingness to comply and be available for all protocol procedures including inpatient confinement for about 3 days
4. Age between 18 and 45 years, inclusive on the day of infusion
5. Body Mass Index (BMI) of > or =18.5 and >or =30 kg/m2 and Weight > or = 50 kg (110 lbs) and < or = 100 kg (220 lbs)
6. In female subject of childbearing potential, a negative serum pregnancy test at screening and negative serum test within 24 hours prior to infusion Note: A woman is considered of childbearing potential unless post-menopausal (> or = 1 year without menses without other known or suspected cause and appropriately elevated FSH) or surgically sterilized via bilateral oophorectomy or hysterectomy
7. Females of childbearing potential and males agree to use acceptable contraception for the duration of the study Note: A highly effective method of birth control is defined as one that results in a low failure rate (i.e., less than 1 percent per year) according to the CDC criteria.30. These include progestin implants, intrauterine devices (IUDs), surgical (hysterectomy or tubal ligation; vasectomy) or abstinence. Use of methods with higher failure rate (such as progestin injectables, combined oral hormonal contraceptives, condoms, and diaphragms) will not be acceptable when used alone, but they could be considered, if used in combination with another method (for example, a female using combined oral contraceptives if her male partner is sterile, or if she and her non-sterile male partner use a double-barrier method), after consultation with the DMID MM. All males will be required to use a barrier method (condoms) for the duration of the study

8. Screening laboratory tests, are in the normal reference range with acceptable exceptions

   Notes:

   1. If urinalysis by dipstick is abnormal, a complete urinalysis with microscopic evaluation will be performed and the results will supersede the results of the dipstick for blood, glucose and protein.
   2. Menstruating females failing inclusion criteria due to a positive blood on urine test (dipstick or microscopic urinalysis) may be retested following cessation of menses. Do not exclude subjects with <5 RBC/HPF.
   3. Other laboratory values that are outside the range of eligibility but are thought to be due to an acute condition or due to collection or laboratory error may be repeated once.
9. Vital signs are within the acceptable range
10. Has adequate venous access for the infusion and blood collection
11. The urine drug screen is negative
12. Willing to abstain from alcohol consumption for a period of 2 days prior to and during the study
13. Available for follow-up for the duration of the study

Exclusion Criteria:

Subjects meeting any of the following exclusion criteria are not eligible for participation.

All must be answered no for the subject to be eligible for study participation

1. History of a chronic medical condition that would either interfere with the accurate assessment of the objectives of the study or increase the risk profile of the subject.

   Note: Chronic medical conditions include diabetes; Asthma requiring use of medication in the year before screening; Autoimmune disorder such as lupus, Wegener's, rheumatoid arthritis, thyroid disease; Coronary artery disease; Chronic hypertension; History of malignancy except low-grade (squamous and basal cell) skin cancer thought to be cured; chronic renal, hepatic, pulmonary, or endocrine disease; myopathy, and neuropathy

2. History of severe allergic reaction of any type to medications, bee stings, food, or environmental factors or hypersensitivity or reaction to immunoglobulins.

   Note: Severe allergic reaction is defined as any of the following: anaphylaxis, urticaria, or angioedema

3. A marked baseline prolongation of QT/QTcF interval (e.g., repeated demonstration of a QTcF interval >450 milliseconds)
4. Clinically significant abnormal electrocardiogram at screening Note: Clinically significant abnormal ECG results include: complete left or right bundle branch block; other ventricular conduction block; 2nd degree or 3rd degree atrioventricular (AV) block; sustained ventricular arrhythmia; sustained atrial arrhythmia; two Premature Ventricular Contractions in a row; pattern of ST elevation felt consistent with cardiac ischemia; or any condition deemed clinically significant by a study investigator
5. Positive serology results for HIV, HBsAg, or HCV antibodies
6. Febrile illness with temperature >37.6°C 7 days prior to dosing
7. Pregnant or breastfeeding
8. Donated whole blood or blood products within 56 days prior to dosing or plans to donate blood prior to the last scheduled visit in the study (Day 121) Note: Blood products are defined as red blood cells, white blood cells, platelets or plasma)
9. Known allergic reactions to doxycycline or to any of the study product components present in the formulation or in the processing, as listed in the Investigator Brochure
10. Treatment with another investigational product within 30 days of dosing, including a drug, vaccine, biologic, device or blood product
11. Treatment with a monoclonal antibody at any time in the past or planned use during the study period

12. Receipt of antibody* or blood transfusion within 6 months of dosing or within 5 half-lives of the specific product given

    • Note: Tetanus Immune Globulin [TIG], Varicella-Zoster Immune Globulin [VZIG], Intravenous Immunoglobulin [IVIG], Intramuscular [IM] gamma globulin
13. Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements
14. Use of H1 antihistamines or beta-blockers within 5 days of dosing
15. Use of any prohibited medication within 30 days prior to study dosing or planned use during the study period Note: Prohibited medications include immunosuppressives (except nonsteroidal antiinflammatory drugs [NSAIDS]); immune modulators; oral corticosteroids (topical/intranasal steroids are acceptable); anti-neoplastic agents; any licensed biologic including monoclonal antibody or vaccine with the exception of licensed influenza vaccine during the flu season, which is allowed 7 days prior to dosing or 7 days after dosing
16. Any specific condition that in the judgment of the investigator precludes participation because it could affect subject safety
17. Plans to enroll or is already enrolled in another clinical trial that could interfere with safety assessment of the investigational product at any time during the study period Note: Includes trials that have a study intervention such as a drug, biologic, or device
18. Is a study site employee or staff who are paid entirely or partially by the NIAID Office of Clinical Research Resources (OCRR) contract for the DMID-funded trial Note: Site employees or staff include the PIs and sub-investigators or staff who are supervised by the PI or Sub-Investigators

Contacts and Locations

Locations

United States, California

WCCT Global Cypress Clinical Pharmacology Unit

Cypress, California, United States, 90630

Sponsors and Collaborators

National Institute of Allergy and Infectious Diseases (NIAID)

More Information

• Responsible Party: National Institute of Allergy and Infectious Diseases (NIAID)
• ClinicalTrials.gov Identifier: NCT03301090
• Other Study ID Numbers: 15-0109; HHSN272201500005I
• First Posted: October 4, 2017
• Last Update Posted: February 1, 2019
• Last Verified: September 22, 2017

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: No

Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):

Adults; Evaluate; Healthy; Immunogenicity; MERS-CoV; Pharmacokinetics; Phase I; Placebo; REGN MERS; Safety; Tolerability

Additional relevant MeSH terms:

Coronavirus Infections; Virus Diseases; Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections